Simplified Chinese
scroll down
09
2025-12
I. Methods for Obtaining the Draft for Public Comment 1. Paper Version: The public may review the document at Beijing Minhai Biotechnology Co., Ltd. 2. Electronic Version: Access via the following link: https://pan.baidu.com/s/1PW6o2p5maEik3zzhazZqUA?pwd=564g; the extraction code is 564g. The public may download the document directly from this URL. II. Scope of the Public Subject to Comment The scope of this public consultation is limited to citizens and legal entities residing in the vicinity of the production workshop construction project for Minhai Biotechnology’s quadrivalent inactivated enterovirus vaccine (Vero cell) who are affected by or have concerns regarding this project.
10
2025-06
In accordance with the requirements of the Measures for Public Participation in Environmental Impact Assessment (Order No. 4 of the Ministry of Ecology and Environment), the following information regarding the environmental impact assessment for the “Construction Project of the Production Workshop for Minhai Biotechnology’s Quadrivalent Inactivated Enterovirus Vaccine (Vero Cell)” is hereby made public: I. Project Overview Project Name: Construction of the Production Workshop for Minhai Biotechnology’s Quadrivalent Inactivated Enterovirus Vaccine (Vero Cell) Project Nature: Expansion Construction Site: Building No. 2, Zone 2B, North Factory Area, Beijing Minhai Biotechnology Co., Ltd., No. 35 Simiao Road, Bio‑Pharmaceutical Industry Base, Daxing District, Beijing Project Undertaker: Beijing Minhai Biotechnology Co., Ltd. Scope of Construction: This project will utilize…
06
2025-01
Detailed Personal Achievements: Nie Xiaoqi is the Deputy General Manager of Beijing Minhai Biotechnology Co., Ltd. and currently serves as the company’s Head of Quality Management. He has previously held positions including Director of the Diphtheria–Tetanus–Pertussis Workshop in Vaccine Department II, Director of Vaccine Department IV, and Head of Production Management. During his tenure in the production system, he successfully facilitated the smooth market launch of eight products, including the Hib–DTP–IPV quadrivalent vaccine, the 23-valent pneumococcal vaccine, the 13-valent pneumococcal vaccine, and the human diploid cell‑derived rabies vaccine. As Head of Quality Management, he has organized a series of training programs on international regulatory requirements for GMP‑related personnel, invited WHO inspectors to provide advisory visits to the company, and recommended quality‑management professionals to attend major international conferences on quality management.
14
2024-10
In accordance with the “Decision of the State Council on Amending the Regulations on Environmental Protection Management of Construction Projects” (State Council Order No. 682) and the “Notice on the Issuance of the Interim Measures for Environmental Protection Acceptance upon Completion of Construction Projects” (Guohuan Gui Huanping [2017] No. 4), the “Environmental Protection Acceptance Report upon Completion (Phase I) for the Minhai Biotechnology International Vaccine Industrial Base Project” is hereby made public as follows: Project Name: Construction of the Minhai Biotechnology International Vaccine Industrial Base (Phase I) Project Undertaker: Beijing Minhai Biotechnology Co., Ltd. Publicized Contents: The environmental protection acceptance report upon completion, along with any other matters requiring clarification.
14
2024-10
In accordance with the “Decision of the State Council on Amending the Regulations on Environmental Protection Management of Construction Projects” (State Council Order No. 682) and the “Notice on the Issuance of the Interim Measures for Environmental Protection Acceptance upon Completion of Construction Projects” (Guohuan Gui Huanping [2017] No. 4), the “Environmental Protection Acceptance Report upon Completion (Phase I) for the Minhai Biotechnology International Vaccine Industrial Base Project” is hereby made public as follows: Project Name: Construction of the Minhai Biotechnology International Vaccine Industrial Base (Phase I) Project Undertaker: Beijing Minhai Biotechnology Co., Ltd. Publicized Contents: The environmental protection acceptance report upon completion, along with any other matters requiring clarification.
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%